SORIN GROUP ITALIA SRL INSPIRE 7 HOLLOW FIBER OXYGENATOR; OXYGENATOR, CARDIOPULMONARY BYPASS
|
Back to Search Results |
|
Model Number 7 DUAL |
Device Problem
Increase in Pressure (1491)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 04/08/2022 |
Event Type
malfunction
|
Manufacturer Narrative
|
Patient information were not provided.Device has not been requested for investigation sorin group (b)(4) manufactures the inspire 7 oxygenator.The incident occurred in (b)(6).If any additional information pertinent to the reported event is obtained, it will be provided in a supplemental report.
|
|
Event Description
|
Sorin group (b)(4) has received a report that, at the beginning of a procedure, transmembrane pressure across an inspire 7 oxygenator increased over 300 mmhg.The gas exchanges performance were satisfying.The procedure was concluded without any issue.There is not report of any patient injury.On (b)(6) 2022, livanova received the pump sheet of the procedure and identified that 1mg of magnesium was administered to patient following transmembrane pressure increase.
|
|
Event Description
|
See intial report.
|
|
Manufacturer Narrative
|
Livanova received a report of increased trans-membrane pressure across an inspire oxygenator 7 dual at the beginning of the surgery and 1 mg of magnesium was administered to patient soon after the increased trans-membrane pressure was detected.No gas exchange performances impact was reported.The procedure was completed with no issue.The customer has provided to livanova the pump sheet of the event.Analysis of provided pump sheet confirmed the increased trans-membrane pressure, the administration of the magnesium to the patient to tackle increased trans-membrane pressure and that the activated clotting time (act) values recorded concomitantly with the increased trans-membrane pressure were below 450 seconds.Ifu's of the inspire oxygenators recommend that the act must always be higher than or equal to 450 seconds to ensure adequate blood anticoagulation within the extracorporeal circulation system.Verification of manufacturing records confirmed that involved device was released as conform according to specification.Review of the livanova complaints database identified another similar event related to the same oxygenator lot.Based on the above and previous similar events, livanova believes the increased hydraulic resistance to passage of blood reported by customer was assigned to undesired cellular activation and buildup of biological material inside circuit due to platelet adhesion and fibrin layer deposition in oxy fibers.High pressure excursion event across oxygenator is a multifactorial phenomenon possibly affected by interaction of multiple contributing factors such as clinical procedure (e.G., surgical material), therapies (e.G., anticoagulant prescription, heparin composition and priming composition) and patient-specific health conditions.The risk is in the acceptable region.No action is deemed necessary.Livanova will keep monitoring the market.
|
|
Search Alerts/Recalls
|
|
|